Pfizer Inc (PFE) 31.67 $PFE
Most active New York Stock Exchange-traded stocks
AP - 42 mins ago
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
KMI: 41.46 (-0.37), RCL: 77.46 (-0.36), GE: 26.09 (-0.29), F: 15.81 (-0.20), S: 4.86 (+0.17), PFE: 31.67 (-0.08), HAL: 40.74 (-0.01), BAC: 17.21 (-0.08), VZ: 48.78 (-0.01), ARO: 2.48 (-0.71)
Final Glance: Pharmaceuticals companies
AP - 42 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 107.56 (-0.16), BAX: 73.57 (-0.16), PFE: 31.67 (-0.08), BMY: 58.89 (-0.14)
Hot Drugmakers Build More Labs, Grab Space In Boston
at Investor's Business Daily - 1 hr 58 mins ago
The greater Boston area has seen an influx of some fast-growing biotechs like Biogen Idec (BIIB) that have been taking lab space, a trend that's driven down vacancy rates in a big way. That's under way while the the biotech sector is surging -- IBD's...
BIIB: 341.18 (-6.16), ARE: 88.12 (+1.73), GILD: 101.82 (+0.94), BAX: 73.57 (-0.16), PFE: 31.67 (-0.08), AMGN: 166.55 (-1.52), AGIO: 104.05 (+2.03)
Tenet Healthcare Names Dr. Freda C. Lewis-Hall to Board of Directors
Business Wire - 2 hrs 45 mins ago
The board of directors of Tenet Healthcare Corporation (NYSE:THC) has appointed Freda C. Lewis-Hall, M.D., executive vice president and chief medical officer of Pfizer Inc., as a new independent director. Dr. Lewis-Hall becomes the board's tenth member.
THC: 48.42 (+1.27), PFE: 31.67 (-0.08)
Can Albert Einstein's Math Get You To The Finish Line? Retirement Portfolio Quarterly Review
George Schneider - at Seeking Alpha - 2 hrs 47 mins ago
MMLP: 33.46 (-0.74), HCP: 45.57 (+0.11), CAG: 36.51 (-0.14), PFE: 31.67 (-0.08), ED: 64.07 (+0.14), BBEP: 11.00 (-0.86), O: 46.16 (-0.12), BMY: 58.89 (-0.14), DRI: 57.85 (-0.26), T: 33.91 (-0.09), STON: 26.67 (-0.20), JNJ: 107.56 (-0.16), CBRL: 128.78 (+0.07), SUI: 58.55 (+0.14), S: 4.86 (+0.17), OHI: 38.42 (+0.15), FUN: 46.02 (-0.12), LINE: 17.05 (-1.20), EPR: 56.75 (+0.43), VZ: 48.78 (-0.01)
Midday Glance: Pharmaceuticals companies
AP - Thu Dec 04, 12:49PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 107.56 (-0.16), BAX: 73.57 (-0.16), PFE: 31.67 (-0.08), BMY: 58.89 (-0.14)
Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative
PR Newswire Europe - Thu Dec 04, 10:40AM CST
Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in paediatric patients. This is the first version of abacavir/lamivudine with scoring to allow for dose adjustment and is also flavoured. The FDA's tentative approval through the President's Emergency Plan for AIDS Relief (PEPFAR) programme means the formulations meet all of the agency's quality, safety and efficacy standards.
PFE: 31.67 (-0.08), MYL: 58.23 (unch), GSK: 45.89 (-0.82)
Pfizer (PFE) Crosses Pivot Point Support at $31.45
Comtex SmarTrend(R) - Thu Dec 04, 10:13AM CST
Shares of Pfizer (NYSE
FE) have bearishly opened below the pivot of $31.61 today and have reached the first support level of $31.45. Investors may be interested in a cross of the next downside pivot targets of $31.15 and $30.68.
PFE: 31.67 (-0.08)
Early Glance: Pharmaceuticals companies
AP - Thu Dec 04, 10:07AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 107.56 (-0.16), BAX: 73.57 (-0.16), PFE: 31.67 (-0.08), BMY: 58.89 (-0.14)
This Pet Food Supplier Is Still In the Hunt for Growth
Rich Duprey, The Motley Fool - Motley Fool - Thu Dec 04, 9:45AM CST
Pet supplies retailers are moving online to bolster sales. Photo: Flickr via Mike Mozart The kennel is getting smaller as pet industry growth is being fueled by consolidation . Privately held pet supplies retailer Petco just announced it was...
ZTS: 44.00 (-0.88), AMZN: 316.93 (+0.43), ABT: 45.49 (-0.19), PETS: 13.52 (-0.09), PFE: 31.67 (-0.08), WMT: 84.76 (-0.18), PETM: 79.11 (-0.33)
Dividend Dogs Of Healthcare: A 29.17% Advantage For The 5 Lowest Price High Yield Stocks
Fredrik Arnold - at Seeking Alpha - Thu Dec 04, 8:37AM CST
SNN: 34.65 (-0.27), VIVO: 16.74 (-0.11), PETS: 13.52 (-0.09), PFE: 31.67 (-0.08), MRK: 60.92 (+0.34), AZN: 73.94 (+0.12), THRX: 12.98 (-0.45), GSK: 45.89 (-0.82), SNY: 46.75 (-1.36), PDLI: 7.83 (-0.11)
5 Prime Dividend Dogs Of Healthcare Hound 11% To 45.4% November Upsides
Fredrik Arnold - at Seeking Alpha - Thu Dec 04, 2:40AM CST
KND: 19.00 (-0.15), VIVO: 16.74 (-0.11), PETS: 13.52 (-0.09), PFE: 31.67 (-0.08), GSK: 45.89 (-0.82), MSA: 54.24 (-1.22), HLS: 41.63 (-0.11), SEM: 14.50 (+0.02), PDLI: 7.83 (-0.11), SNN: 34.65 (-0.27), AZN: 73.94 (+0.12), MRK: 60.92 (+0.34), TRIB: 16.90 (+0.39), TEVA: 57.50 (+0.22), THRX: 12.98 (-0.45), SNY: 46.75 (-1.36)
Puma Biotechnology Down on Delay in Neratinib NDA Filing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 4:10PM CST
Shares of Puma Biotechnology, Inc. (PBYI) plunged significantly in after-market hours trading following the company's announcement that the NDA on pipeline candidate neratinib (PB272) will be delayed till the first quarter of 2016.
BIIB: 341.18 (-6.16), PFE: 31.67 (-0.08), PBYI: 195.55 (-2.12)
Phase 3 Results Published in The New England Journal of Medicine Show Superiority of Pfizer's XALKORI(R) (crizotinib) Compared to Platinum-Based Chemotherapy in Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer
Business Wire - Wed Dec 03, 4:07PM CST
Pfizer Inc. (NYSE FE) announced today the publication of results from the PROFILE 1014 study in the December 4 issue of The New England Journal of Medicine. PROFILE 1014 is a Phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor XALKORI(R) (crizotinib) in previously untreated patients with ALK-positive advanced non-small cell lung cancer (NSCLC). These results demonstrated that XALKORI 250 mg twice daily significantly prolonged progression-free survival (PFS) in previously untreated patients with ALK-positive advanced NSCLC when compared to standard platinum-based chemotherapy regimens. The adverse events were consistent with the known safety profile for XALKORI.
PFE: 31.67 (-0.08)
Diplomat selected as a limited-distribution pharmacy partner by Pfizer; Diplomat to dispense Xalkori®, Bosulif®, Sutent® and Inlyta®
PR Newswire - Wed Dec 03, 3:37PM CST
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced today that it has been selected to Pfizer Inc.'s limited-distribution panel for Xalkori®, Bosulif®, Inlyta® and Sutent®.
DPLO: 27.16 (+0.40), PFE: 31.67 (-0.08)
WADA signs deal with US-based drug maker
AP - Wed Dec 03, 11:11AM CST
MONTREAL (AP) — The World Anti-Doping Agency has signed a deal with a leading U.S.-based drug maker to share information about new performance-enhancing substances that could be misused by athletes.
PFE: 31.67 (-0.08)
Most active New York Stock Exchange-traded stocks
AP - 42 mins ago
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
KMI: 41.46 (-0.37), RCL: 77.46 (-0.36), GE: 26.09 (-0.29), F: 15.81 (-0.20), S: 4.86 (+0.17), PFE: 31.67 (-0.08), HAL: 40.74 (-0.01), BAC: 17.21 (-0.08), VZ: 48.78 (-0.01), ARO: 2.48 (-0.71)
Final Glance: Pharmaceuticals companies
AP - 42 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 107.56 (-0.16), BAX: 73.57 (-0.16), PFE: 31.67 (-0.08), BMY: 58.89 (-0.14)
Hot Drugmakers Build More Labs, Grab Space In Boston
at Investor's Business Daily - 1 hr 58 mins ago
The greater Boston area has seen an influx of some fast-growing biotechs like Biogen Idec (BIIB) that have been taking lab space, a trend that's driven down vacancy rates in a big way. That's under way while the the biotech sector is surging -- IBD's...
BIIB: 341.18 (-6.16), ARE: 88.12 (+1.73), GILD: 101.82 (+0.94), BAX: 73.57 (-0.16), PFE: 31.67 (-0.08), AMGN: 166.55 (-1.52), AGIO: 104.05 (+2.03)
Tenet Healthcare Names Dr. Freda C. Lewis-Hall to Board of Directors
Business Wire - 2 hrs 45 mins ago
The board of directors of Tenet Healthcare Corporation (NYSE:THC) has appointed Freda C. Lewis-Hall, M.D., executive vice president and chief medical officer of Pfizer Inc., as a new independent director. Dr. Lewis-Hall becomes the board's tenth member.
THC: 48.42 (+1.27), PFE: 31.67 (-0.08)
Can Albert Einstein's Math Get You To The Finish Line? Retirement Portfolio Quarterly Review
George Schneider - at Seeking Alpha - 2 hrs 47 mins ago
MMLP: 33.46 (-0.74), HCP: 45.57 (+0.11), CAG: 36.51 (-0.14), PFE: 31.67 (-0.08), ED: 64.07 (+0.14), BBEP: 11.00 (-0.86), O: 46.16 (-0.12), BMY: 58.89 (-0.14), DRI: 57.85 (-0.26), T: 33.91 (-0.09), STON: 26.67 (-0.20), JNJ: 107.56 (-0.16), CBRL: 128.78 (+0.07), SUI: 58.55 (+0.14), S: 4.86 (+0.17), OHI: 38.42 (+0.15), FUN: 46.02 (-0.12), LINE: 17.05 (-1.20), EPR: 56.75 (+0.43), VZ: 48.78 (-0.01)
Midday Glance: Pharmaceuticals companies
AP - Thu Dec 04, 12:49PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 107.56 (-0.16), BAX: 73.57 (-0.16), PFE: 31.67 (-0.08), BMY: 58.89 (-0.14)
Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative
PR Newswire Europe - Thu Dec 04, 10:40AM CST
Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in paediatric patients. This is the first version of abacavir/lamivudine with scoring to allow for dose adjustment and is also flavoured. The FDA's tentative approval through the President's Emergency Plan for AIDS Relief (PEPFAR) programme means the formulations meet all of the agency's quality, safety and efficacy standards.
PFE: 31.67 (-0.08), MYL: 58.23 (unch), GSK: 45.89 (-0.82)
Pfizer (PFE) Crosses Pivot Point Support at $31.45
Comtex SmarTrend(R) - Thu Dec 04, 10:13AM CST
Shares of Pfizer (NYSE
FE) have bearishly opened below the pivot of $31.61 today and have reached the first support level of $31.45. Investors may be interested in a cross of the next downside pivot targets of $31.15 and $30.68. PFE: 31.67 (-0.08)
Early Glance: Pharmaceuticals companies
AP - Thu Dec 04, 10:07AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 107.56 (-0.16), BAX: 73.57 (-0.16), PFE: 31.67 (-0.08), BMY: 58.89 (-0.14)
This Pet Food Supplier Is Still In the Hunt for Growth
Rich Duprey, The Motley Fool - Motley Fool - Thu Dec 04, 9:45AM CST
Pet supplies retailers are moving online to bolster sales. Photo: Flickr via Mike Mozart The kennel is getting smaller as pet industry growth is being fueled by consolidation . Privately held pet supplies retailer Petco just announced it was...
ZTS: 44.00 (-0.88), AMZN: 316.93 (+0.43), ABT: 45.49 (-0.19), PETS: 13.52 (-0.09), PFE: 31.67 (-0.08), WMT: 84.76 (-0.18), PETM: 79.11 (-0.33)
Dividend Dogs Of Healthcare: A 29.17% Advantage For The 5 Lowest Price High Yield Stocks
Fredrik Arnold - at Seeking Alpha - Thu Dec 04, 8:37AM CST
SNN: 34.65 (-0.27), VIVO: 16.74 (-0.11), PETS: 13.52 (-0.09), PFE: 31.67 (-0.08), MRK: 60.92 (+0.34), AZN: 73.94 (+0.12), THRX: 12.98 (-0.45), GSK: 45.89 (-0.82), SNY: 46.75 (-1.36), PDLI: 7.83 (-0.11)
5 Prime Dividend Dogs Of Healthcare Hound 11% To 45.4% November Upsides
Fredrik Arnold - at Seeking Alpha - Thu Dec 04, 2:40AM CST
KND: 19.00 (-0.15), VIVO: 16.74 (-0.11), PETS: 13.52 (-0.09), PFE: 31.67 (-0.08), GSK: 45.89 (-0.82), MSA: 54.24 (-1.22), HLS: 41.63 (-0.11), SEM: 14.50 (+0.02), PDLI: 7.83 (-0.11), SNN: 34.65 (-0.27), AZN: 73.94 (+0.12), MRK: 60.92 (+0.34), TRIB: 16.90 (+0.39), TEVA: 57.50 (+0.22), THRX: 12.98 (-0.45), SNY: 46.75 (-1.36)
Puma Biotechnology Down on Delay in Neratinib NDA Filing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 4:10PM CST
Shares of Puma Biotechnology, Inc. (PBYI) plunged significantly in after-market hours trading following the company's announcement that the NDA on pipeline candidate neratinib (PB272) will be delayed till the first quarter of 2016.
BIIB: 341.18 (-6.16), PFE: 31.67 (-0.08), PBYI: 195.55 (-2.12)
Phase 3 Results Published in The New England Journal of Medicine Show Superiority of Pfizer's XALKORI(R) (crizotinib) Compared to Platinum-Based Chemotherapy in Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer
Business Wire - Wed Dec 03, 4:07PM CST
Pfizer Inc. (NYSE
FE) announced today the publication of results from the PROFILE 1014 study in the December 4 issue of The New England Journal of Medicine. PROFILE 1014 is a Phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor XALKORI(R) (crizotinib) in previously untreated patients with ALK-positive advanced non-small cell lung cancer (NSCLC). These results demonstrated that XALKORI 250 mg twice daily significantly prolonged progression-free survival (PFS) in previously untreated patients with ALK-positive advanced NSCLC when compared to standard platinum-based chemotherapy regimens. The adverse events were consistent with the known safety profile for XALKORI. PFE: 31.67 (-0.08)
Diplomat selected as a limited-distribution pharmacy partner by Pfizer; Diplomat to dispense Xalkori®, Bosulif®, Sutent® and Inlyta®
PR Newswire - Wed Dec 03, 3:37PM CST
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced today that it has been selected to Pfizer Inc.'s limited-distribution panel for Xalkori®, Bosulif®, Inlyta® and Sutent®.
DPLO: 27.16 (+0.40), PFE: 31.67 (-0.08)
WADA signs deal with US-based drug maker
AP - Wed Dec 03, 11:11AM CST
MONTREAL (AP) — The World Anti-Doping Agency has signed a deal with a leading U.S.-based drug maker to share information about new performance-enhancing substances that could be misused by athletes.
PFE: 31.67 (-0.08)
